TIDMOPTI
RNS Number : 0234T
OptiBiotix Health PLC
20 July 2022
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Commercial and scientific update
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, provides an update on recent
scientific and commercial activities .
1. Launch of WellBiome at IFT, USA: The Company has developed a
new formulation of WellBiome(R) as part of its health and wellness
portfolio to support healthy ageing. The product has several
European and USA health claims allowing on pack claims for heart
health, bone health, cognitive health and metabolic health. The
formulation is protected by a portfolio of trademarks and patents
and was soft launched at IFT in Chicago, USA. The launch of
WellBiome(R) is part of a strategy of extending the Company's
product portfolio into other areas of healthcare.
2. Clinical Study with University of Hull: The Company is
conducting a human intervention study with The University of Hull
investigating the impact of WellBiome(R) on reducing post operative
complications and hospital stay. The study is funded by the
University of Hull with an intended start date either in Q4 2022 or
Q1 2023, subject to NHS ethics approval. There is growing interest
in the potential of prebiotics in post operative care as a means of
reducing pain, surgical complications, and the length of hospital
stay . Whilst exploratory, if successful, this study could open up
opportunities for WellBiome(R) in healthcare.
3. LeanBiome (R) Certified as an Informed Ingredient for Sports:
The Company is pleased to announce that it has received approval
for LeanBiome(R) as an Informed Ingredient (see
https://ingredient.wetestyoutrust.com/ingredient-search/optibiotix/leanbiome
). This is an industry certification which demonstrates that
LeanBiome(R) has been through rigorous independent testing by an
authorised body to confirm that it is free from substances that are
banned in sport. The risk of contamination with low levels of
substances prohibited by the World Anti-Doping Agency (WADA) is a
serious issue in sport. Certification of LeanBiome (R) as an
informed ingredient is an important step in attracting major sports
nutrition companies to incorporate LeanBiome(R) in their sports
nutrition products.
4. SweetBiotix(R) Publication: The Company is pleased to
announce the publication of a study on the prebiotic activity and
sweetness of one of its SweetBiotix (R) products in a peer reviewed
journal (see https://pubs.acs.org/doi/10.1021/acs.jafc.2c01363 ).
The study reports that enzymatic synthesis of modified mogroside
and galacto-oligosaccharides (GOS) from lactose was able to
generate products which positively modulated the microbiome with a
sweetness profile similar to sugar. The products sweetness, bulking
and prebiotic fibre properties could make it a suitable replacement
to sugar in everyday products. This is one of a number of
SweetBiotix (R) products developed for different application types
in food, beverages, and dairy. Publications by independent authors
in peer reviewed journals are critical in establishing industry
awareness and credibility in the Company's products and provide
valuable marketing assets to support product launches.
5. New Product Development-Extruded Puffs : The Company has been
developing low calorie, high prebiotic fibre puffs that make you
feel full for longer and reduce your food cravings as an extension
of its SlimBiome(R) and LeanBiome(R) ranges. Taste testing of four
flavours has been successful and investors should start seeing
these products launched online and with partners later this year.
This is all part of an ongoing product development programme with
partners to extend the range of products containing SlimBiome(R)
and LeanBiome(R).
My Protein Breakfast Smoothie: The Company was pleased to see
the recent launch of a breakfast smoothie range containing
LeanBiome(R) by The Hut Group as part of its MYProtein range.
Stephen O'Hara, CEO of OptiBiotix Health plc c o m mented: " The
Company has been working to develop new first-generation products
like LeanBiome (R) and WellBiome(R) into the sports nutrition and
health and wellbeing market respectively, extend its product range
for SlimBiome (R) , and provide scientific publications to support
partners launching second generation products like SweetBiotix (R)
and our microbiome modulators. This is all part of a process of
gradually increasing the range of products, applications, and
territories creating the potential to open larger market
opportunities putting the Company in a strong position for future
growth in this exciting area of healthcare."
The Directors of the Company are responsible for the release of
this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDEALXNFSLAEFA
(END) Dow Jones Newswires
July 20, 2022 02:00 ET (06:00 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
